KYMR Q2 2024 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+55.3% YoY

Gross Profit

$26M100.0% margin

Operating Income

-$51M-198.5% margin

Net Income

-$42M-164.0% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

+149.3%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$48M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$826M

Total Liabilities

$141M

Stockholders' Equity

$685M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$17M	+55.3%
Gross Profit	$26M	$17M	+55.3%
Operating Income	-$51M	-$43M	-17.4%
Net Income	-$42M	-$39M	-8.4%